Objectives: Intravesical therapy with Bacillus Calmette-Guérin and chemotherapy are an integral part in the management of non-muscle invasive bladder cancer (NMIBC), which is administered after transurethral surgical resection (TUR) of tumour to prevent relapse and progression of the disease. However, these therapies frequently cause side effects such as cystitis-like symptoms, which often can lead to treatment discontinuation. The purpose of this investigation was to evaluate the effect of intravesical administration of adelmidrol (AD) and hyaluronic acid (HA) on the typical symptoms in patients undergoing intravesical anticancer treatment for NMIBC, after TUR. Materials and Methods: Thirty-one patients, who underwent TUR for NMIBC and had completed a cycle of intravesical anticancer treatment associated with AD + HA instillations, were considered for this retrospective investigation. For all patients, the main collected outcomes were: Pain intensity, urgency and discomfort related to frequent micturition (FM-related discomfort) evaluated by visual analogue scale, symptoms frequency and patients degree of concern evaluated by pelvic pain and urgency/frequency patient symptom scale, and health-related quality of life detected with the 12-item short form survey. Results: Intravesical instillation of AD + HA as an add-on treatment to intravesical anticancer therapy allowed to keep under control pain intensity, urgency and FM-related discomfort, enabling all patients to complete the entire course of anticancer treatment. Conclusion: This retrospective investigation shows the potential efficacy of AD + HA to control anticancer treatment-related side effects. Larger randomized controlled studies are needed to confirm these encouraging results.
Corresponding Author: CANEPA G.|